[Featured Stock] ABL Bio Hits Record High on News of 4 Trillion Won Technology Export Deal

ABL Bio is showing strong performance in the early trading session. The news that it signed a trillion-won scale technology export contract with a British pharmaceutical company, marking the second largest deal in K-bio history, is believed to have boosted investor sentiment.

At 9:08 a.m. on the 8th, ABL Bio was trading at 49,050 won, up 10.85% (4,800 won) from the previous close. During the session, the price surged to 51,200 won, setting a new 52-week high.

Previously, ABL Bio announced that it had signed a technology export contract worth a total of 4.1 trillion won with the British pharmaceutical company GlaxoSmithKline (GSK). The goal is to develop a new treatment for degenerative brain diseases based on the blood-brain barrier (BBB) shuttle platform 'Grabody-B.'

This trillion-won scale contract is also seen as proof of ABL Bio's technological capabilities. In particular, the 4 trillion won scale is the first since June 2020, when Alteogen signed a technology export contract worth 4.67 trillion won with Merck.

Junyoung Kim, a researcher at Meritz Securities, explained, "A detailed update is expected at the briefing scheduled for the 9th. The main investment points are additional technology transfers driven by increasing demand for the BBB shuttle and the announcement of Phase 1 clinical trial results for ABL301, which is currently undergoing Phase 1 clinical research targeting Parkinson's disease."

This content was produced with the assistance of AI translation services.